A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer.

Trial Profile

A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Cisplatin; Pemetrexed
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Spinnaker
  • Sponsors Eli Lilly
  • Most Recent Events

    • 23 Jun 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
    • 11 Oct 2010 As a result of the primary endpoint of the trial not being met, Lilly will not submit marketing authorization applications for pemetrexed in this indication with either the US FDA or the EMA in Europe, as reported in an Eli Lilly media release.
    • 11 Oct 2010 Primary endpoint 'Overall survival' has not been met, as reported in a media release from Eli Lilly.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top